{
  "title": "Paper_286",
  "abstract": "pmc Haematologica Haematologica 820 haematol HAEMA Haematologica 0390-6078 1592-8721 Ferrata Storti Foundation PMC12485318 PMC12485318.1 12485318 12485318 40045904 10.3324/haematol.2025.287442 1 Comment Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on “Targeted anti-cancer agents and risk of venous thromboembolism” Duane Catherine  1  2 Glavey Siobhan  1  2 Quinn John  1  2 Murphy Philip  1  2 Contribbutions 1 2 RCSI University of Medicine and Health Sciences Ireland C. DUANE - catherineduane@rcsi.ie  Disclosures No conflicts of interest to declare. 06 3 2025 01 10 2025 110 10 498052 2552 2553 23 1 2025 27 1 2025 06 03 2025 02 10 2025 02 10 2025 Copyright© 2025 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License ( by-nc 4.0 pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement no pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes In their recent publication, Verso et al 1 2 3 4 5 6 Immunomodulatory drugs exert their targeted anti-myeloma effects through cereblon (CRBN) E3 ligase binding, which facilitates the degradation of two key B-cell transcription factors: Ikaros (IKZF1) and Aiolos (IKZF3). 7 8 9 10 11 Following recognition of the elevated VTE risk associated with IMiD therapy, the International Myeloma Working Group (IMWG) published thromboprophylaxis practice guidelines in 2008, recommending aspirin for low-risk patients and low-molecular-weight heparin (LMWH) for high-risk patients. 12 5 6 13 In conclusion, IMiD are an important class of targeted anti-cancer drugs associated with a well-documented increased risk of VTE in MM. However, despite recent Intergroupe Francophone du Myélome recommendations that favor LMWH or DOAC instead of aspirin for all patients receiving IMiD-dexamethasone therapy, there remains a lack of international consensus regarding optimal thromboprophylaxis. 14 15 References 1. Verso M Moik F Graziani M Targeted anti-cancer agents and risk of venous thromboembolism Haematologica 2024 109 12 3868 3878 39618297 10.3324/haematol.2023.284778 PMC11609817 2. Palumbo A Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance Ther Adv Drug Saf 2012 3 5 255 266 25083240 10.1177/2042098612452291 PMC4110867 3. Mulder FI Horváth-Puhó E van Es N Venous thromboembolism in cancer patients: a population-based cohort study Blood 2021 137 14 1959 1969 33171494 10.1182/blood.2020007338 4. Rajkumar SV Jacobus S Callander NS Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 2010 11 1 29 37 19853510 10.1016/S1470-2045(09)70284-0 PMC3042271 5. Sborov DW Baljevic M Reeves B Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study Br J Haematol 2022 199 3 355 365 36111391 10.1111/bjh.18432 PMC9825872 6. Bradbury CA Craig Z Cook G Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials Blood 2020 136 9 1091 1104 32438407 10.1182/blood.2020005125 PMC7453153 7. Krönke J Udeshi ND Narla A Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells Science 2014 343 6168 301 305 24292625 10.1126/science.1244851 PMC4077049 8. Dredge K Horsfall R Robinson SP Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res. 2005 69 1-2 56 63 15797261 10.1016/j.mvr.2005.01.002 9. Eby C Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias Br J Haematol 2009 145 2 151 163 19210509 10.1111/j.1365-2141.2008.07577.x 10. van Marion AM Auwerda JJ Lisman T Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens Leuk Res 2008 32 7 1078 1084 18241919 10.1016/j.leukres.2007.12.002 11. Johnson DC Corthals S Ramos C Genetic associations with thalidomide-mediated venous thrombotic events in myeloma identified using targeted genotyping Blood 2008 112 13 4924 4934 18805967 10.1182/blood-2008-02-140434 PMC3601865 12. Palumbo A Rajkumar SV Dimopoulos MA International Myeloma Working Group, prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 2008 22 2 414 423 18094721 10.1038/sj.leu.2405062 13. Charalampous C Goel U Kapoor P Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival Am J Hematol 2023 98 3 413 420 36588396 10.1002/ajh.26806 14. Frenzel L Decaux O Macro M Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group Thromb Res 2024 233 153 164 38064842 10.1016/j.thromres.2023.11.021 15. Kapur S Feehan K Mosiman S Real-world validation of VTE risk models in newly diagnosed multiple myeloma in a community setting Blood. 2021 138 2971 ",
  "metadata": {
    "Title of this paper": "Real-world validation of VTE risk models in newly diagnosed multiple myeloma in a community setting",
    "Journal it was published in:": "Haematologica",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485318/"
  }
}